Warner-Lambert’s Nipent (pentostatin)
Executive Summary
New indication as first-line treatment for hairy cell leukemia will be considered by FDA's Oncologic Drugs Advisory Committee on March 1. Also on the committee's agenda for the same day are Burroughs Wellcome's Zyloprim injection (allopurinol) for "the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid," and Scios-Nova's Pergamid (perfosfamide) for bone marrow purging, FDA announced. Pergamid was to have been reviewed by the panel on Nov. 17; that meeting was canceled due to a water main break at FDA's Parklawn building. The March 1 meeting will begin at 8:00 a.m. in Conference Rooms D & E of the Parklawn building in Rockville, Md.
|
New indication as first-line treatment for hairy cell leukemia will
be considered by FDA's Oncologic Drugs Advisory Committee on March
1. Also on the committee's agenda for the same day are Burroughs
Wellcome's Zyloprim injection (allopurinol) for "the management of
patients with leukemia, lymphoma and malignancies who are receiving
cancer therapy which causes elevations of serum and urinary uric
acid," and Scios-Nova's Pergamid (perfosfamide) for bone marrow
purging, FDA announced. Pergamid was to have been reviewed by the
panel on Nov. 17; that meeting was canceled due to a water main
break at FDA's Parklawn building. The March 1 meeting will begin at
8:00 a.m. in Conference Rooms D & E of the Parklawn building in
Rockville, Md. |